HIV And AIDS

FDA Approves Expanded Use Of ISENTRESS® (raltegravir) In Combination Therapy For Adult Patients With HIV-1 Infection
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for ISENTRESS®. The broadened indication now includes use in the treatment of adult patients starting HIV-1 therapy for the first time (treatment-naïve), as well as in treatment-experienced adult patients. ISENTRESS is used in combination with other antiretroviral (ARV) medicines for the treatment of HIV-1 infection in adult patients.

Scientists Examine HIV's Effect On Immune System
A study by researchers from Duke University and the University of North Carolina-Chapel Hill and published in PLoS Medicine has found that upon infection "three lines of attack by the immune system are quickly neutralized by HIV," findings they hope "will provide a better understanding of how to develop a vaccine to protect against the virus," the